Anne Marie Taburet

Summary

Country: France

Publications

  1. ncbi request reprint In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation
    Denis Projean
    AstraZeneca R and D Montreal, 7171 Frederick Banting, Ville Saint Laurent, Quebec, Canada, H4S 1Z9
    Drug Metab Dispos 31:748-54. 2003
  2. pmc Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda
    Laurence Ahoua
    Clinical Research Department, Epicentre, Paris, France
    BMC Pediatr 11:67. 2011
  3. ncbi request reprint Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies
    Anne Marie Taburet
    Clinical Pharmacy, Hospital Bicetre, Assistance Publique Hopitaux de Paris, France
    Clin Pharmacokinet 42:1179-91. 2003
  4. ncbi request reprint Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus
    Anne Marie Taburet
    Clinical Pharmacy Department, Hospitaux de Paris, Kremlin Bicetre, Paris France
    Clin Pharmacol Ther 75:310-23. 2004
  5. pmc Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients
    Anne Marie Taburet
    Clinical Pharmacy, Hospital Bicêtre Assistance Publique Hôpitaux de Paris, 78 rue du General Leclerc, 94270 Kremlin Bicetre, France
    Antimicrob Agents Chemother 48:2091-6. 2004
  6. ncbi request reprint Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure
    Gilles Raguin
    Service de Maladies Infectieuses, Hopital Saint Antoine, Assistance Publique Hopitaux de Paris, Paris, France
    Antivir Ther 9:615-25. 2004
  7. ncbi request reprint Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir
    Clotilde Le Tiec
    Clinical Pharmacy Department, Hopital Bicetre, Assistance Publique Hopitaux de Paris AP HP, Paris, France
    Clin Pharmacokinet 44:1035-50. 2005
  8. ncbi request reprint Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial
    Christophe Piketty
    Department of Immunology, Hôpital Georges Pompidou, Assistance Publique Hopitaux de Paris, Paris, France
    Antivir Ther 11:213-21. 2006
  9. pmc Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen
    Aurélie Barrail-Tran
    Assistance Publique Hopitaux de Paris, Hopital Bicetre, Service de Pharmacie Clinique, Paris, France
    Antimicrob Agents Chemother 52:1642-6. 2008
  10. pmc Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial
    Lauriane Goldwirt
    Department of Clinical Pharmacy, Bicetre Hospital, Assistance Publique Hopitaux de Paris, and University Paris 11, Le Kremlin Bicetre, France
    Antimicrob Agents Chemother 55:3613-5. 2011

Collaborators

Detail Information

Publications32

  1. ncbi request reprint In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation
    Denis Projean
    AstraZeneca R and D Montreal, 7171 Frederick Banting, Ville Saint Laurent, Quebec, Canada, H4S 1Z9
    Drug Metab Dispos 31:748-54. 2003
    ..At therapeutically relevant concentrations ( approximately 100 microM CQ in the liver), CYP2C8, CYP3A4, and, to a much lesser extent, CYP2D6 are expected to account for most of the CQ N-desethylation...
  2. pmc Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda
    Laurence Ahoua
    Clinical Research Department, Epicentre, Paris, France
    BMC Pediatr 11:67. 2011
    ..We describe treatment outcomes in children treated in rural Uganda after 1 and 2 years of ART start...
  3. ncbi request reprint Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies
    Anne Marie Taburet
    Clinical Pharmacy, Hospital Bicetre, Assistance Publique Hopitaux de Paris, France
    Clin Pharmacokinet 42:1179-91. 2003
    ..Preliminary results from these small pilot studies suggest that once-daily administration of antiretrovirals is a feasible approach. Large comparative trials are needed before the real benefits of such a strategy can be fully assessed...
  4. ncbi request reprint Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus
    Anne Marie Taburet
    Clinical Pharmacy Department, Hospitaux de Paris, Kremlin Bicetre, Paris France
    Clin Pharmacol Ther 75:310-23. 2004
    ..This pharmacokinetic study was designed to characterize interactions between amprenavir and the lopinavir-ritonavir combination in patients infected with human immunodeficiency virus in whom previous antiretroviral therapy had failed...
  5. pmc Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients
    Anne Marie Taburet
    Clinical Pharmacy, Hospital Bicêtre Assistance Publique Hôpitaux de Paris, 78 rue du General Leclerc, 94270 Kremlin Bicetre, France
    Antimicrob Agents Chemother 48:2091-6. 2004
    ..The median decreases in the HIV RNA loads at week 2 and week 6 were 0.1 and 0.2 log copies/ml, respectively. In summary, our data are consistent with the existence of a significant interaction between atazanavir and tenofovir DF...
  6. ncbi request reprint Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure
    Gilles Raguin
    Service de Maladies Infectieuses, Hopital Saint Antoine, Assistance Publique Hopitaux de Paris, Paris, France
    Antivir Ther 9:615-25. 2004
    ....
  7. ncbi request reprint Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir
    Clotilde Le Tiec
    Clinical Pharmacy Department, Hopital Bicetre, Assistance Publique Hopitaux de Paris AP HP, Paris, France
    Clin Pharmacokinet 44:1035-50. 2005
    ..Major advantages of atazanavir to date are its simplicity of administration (once-daily administration) and its less undesirable effect on the lipid profiles in patients...
  8. ncbi request reprint Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial
    Christophe Piketty
    Department of Immunology, Hôpital Georges Pompidou, Assistance Publique Hopitaux de Paris, Paris, France
    Antivir Ther 11:213-21. 2006
    ..Ritonavir (RTV)-boosted atazanavir (ATV) and tenofovir disoproxil fumarate (TDF-DF) are promising in highly experienced patients because of their pharmacokinetic profile, activity, safety and resistance properties...
  9. pmc Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen
    Aurélie Barrail-Tran
    Assistance Publique Hopitaux de Paris, Hopital Bicetre, Service de Pharmacie Clinique, Paris, France
    Antimicrob Agents Chemother 52:1642-6. 2008
    ..High amprenavir and lopinavir concentrations in these patients might explain why plasma concentrations and the phenotypic IQ have poor predictive value...
  10. pmc Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial
    Lauriane Goldwirt
    Department of Clinical Pharmacy, Bicetre Hospital, Assistance Publique Hopitaux de Paris, and University Paris 11, Le Kremlin Bicetre, France
    Antimicrob Agents Chemother 55:3613-5. 2011
    ..49, 0.76, and 0.67 and 0.82, 0.68, and 0.64 for tipranavir and darunavir, respectively. The virologic consequences of these drug interactions have yet to be determined...
  11. ncbi request reprint Determination of amprenavir total and unbound concentrations in plasma by high-performance liquid chromatography and ultrafiltration
    Aurélie Barrail
    Clinical Pharmacy, Hospital Bicetre, Assistance Publique Hopitaux de Paris, France
    Ther Drug Monit 28:89-94. 2006
    ..It remains to be seen whether measurement of unbound concentrations, rather than total concentrations, could improve therapeutic drug monitoring...
  12. pmc Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children
    Caroline Barau
    Department of Clinical Pharmacy, Assistance Publique Hopitaux de Paris, Hôpitaux Universitaires Paris Sud, Le Kremlin Bicetre, France
    Br J Clin Pharmacol 74:515-24. 2012
    ....
  13. ncbi request reprint Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients
    Aurélie Barrail-Tran
    AP HP, Hospital Bicetre, Paris, France
    AIDS 24:2581-3. 2010
    ..118 and 3837 vs. 2241 ng/ml) and darunavir area under the curve (AUC(12h)) (50 083 vs. 36 277 ng h/ml). All pharmacokinetic parameters appeared to be highly variable regardless to the addition of etravirine...
  14. ncbi request reprint High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy
    Cecile Goujard
    Internal Medicine Unit, Bicetre University Hospital, AP HP, Kremlin Bicetre, France
    Clin Pharmacokinet 44:1267-78. 2005
    ....
  15. doi request reprint Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients
    Caroline Barau
    Department of Clinical Pharmacy, Bicetre Hospital, Assistance Publique Hopitaux de Paris, Le Kremlin Bicetre, France
    Liver Transpl 17:1152-8. 2011
    ..Furthermore, these results suggest that the coadministration of MPA with rifampin should be avoided...
  16. pmc High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial
    Caroline Barau
    Department of Clinical Pharmacy, Bicetre Hospital, Assistance Publique Hopitaux de Paris, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre, France
    Antimicrob Agents Chemother 54:937-9. 2010
    ..The median semen-to-plasma ratio of raltegravir concentration was 1.42 (range, 0.52 to 6.66), indicating good although variable levels of drug penetration of raltegravir in the seminal compartment...
  17. doi request reprint Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors
    Benoit Chauvin
    Clinical Pharmacy Department, Assistance Publique Hopitaux de Paris, Hopital Bicetre, Hôpitaux Universitaires Paris Sud AP HP, 78 rue du General Leclerc, 94270, Kremlin Bicetre, France
    Clin Pharmacokinet 52:815-31. 2013
    ..Effectiveness and occurrence of adverse effects should be monitored at regular time intervals. ..
  18. ncbi request reprint Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy
    Karl Brendel
    INSERM E0357, Department of Epidemiology, Biostatistics and Clinical Research, AP HP, Bichat University Hospital, Paris, France
    Fundam Clin Pharmacol 19:373-83. 2005
    ....
  19. doi request reprint Falsely elevated whole blood tacrolimus concentrations due to interference in an affinity column-mediated immunoassay method on Xpand dimension
    Caroline Barau
    Department of Clinical Pharmacy, Bicetre Hospital, APHP, 78 rue du General Leclerc, Le Kremlin Bicetre, France
    Ther Drug Monit 31:267-8. 2009
    ..However, it would be necessary to identify this type of interference to measure tacrolimus concentration with another method to avoid analytical error, which may lead to a poor clinical outcome...
  20. doi request reprint Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients
    Jean Francois Delfraissy
    AP HP, Department of Internal Medicine and Infectious Diseases, Bicetre University Hospital, Le Kremlin Bicetre, France
    AIDS 22:385-93. 2008
    ..Guidelines for the use of antiretroviral agents for HIV-1 infection recommend combining at least three agents. The toxicity, cost, and complexity of such regimens warrant the search for other options...
  21. ncbi request reprint Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia
    Laurent Ferradini
    Epicentre, Paris, France
    AIDS 21:2293-301. 2007
    ..We report the outcomes at 24 months of antiretroviral therapy (ART) in patients treated in a Médecins Sans Frontières/Ministry of Health programme in Cambodia...
  22. ncbi request reprint Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study
    Elina Teicher
    Internal Medicine and Infectious Diseases Department, Hopital Paul Brousse, Assistance Publique Hopitaux de Paris AP HP, Paris, France
    Clin Pharmacokinet 46:941-52. 2007
    ..To characterise the interactions between tacrolimus and antiretroviral drug combinations in hepatitis C virus-HIV co-infected patients who had received a liver transplant...
  23. pmc Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART
    Xaviere Panhard
    INSERM U738, 16 rue Henri Huchard, 75018, Paris, France
    Eur J Clin Pharmacol 63:1019-29. 2007
    ....
  24. ncbi request reprint Virological and immunological impact of non-nucleoside reverse transcriptase inhibitor withdrawal in HIV-infected patients with multiple treatment failures
    Christophe Piketty
    AIDS 18:1469-71. 2004
    ..The data suggest that in the presence of specific resistance mutations NNRTIexert no residual antiretroviral activity and could be withdrawn without viral rebound...
  25. ncbi request reprint Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease
    Rami Kotb
    Department of Internal Medicine, CHU Bicetre, AP HP, Le Kremlin Bicetre, Cedex, France
    Eur J Haematol 76:269-71. 2006
    ..Potential interactions exist between antiretroviral drugs, in particular protease inhibitors, and anti-neoplastic ones, but their impact in terms of clinical and haematological adverse events remains unclear...
  26. ncbi request reprint Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy
    Laurence Morand-Joubert
    AP HP, Centre Hospitalo Universitaire Saint Antoine, Paris, France
    Antivir Ther 11:143-54. 2006
    ....
  27. ncbi request reprint Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients
    Xaviere Panhard
    INSERM U738, Paris, France
    Stat Med 26:1268-84. 2007
    ..We applied the Wald test to the pharmacokinetic interaction of tenofovir on atazanavir, a novel protease inhibitor. A significant decrease of the area under the curve of atazanavir was found when patients received tenofovir...
  28. ncbi request reprint Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results
    Gilles Raguin
    Departement de Medecine, Hôpital Croix St Simon, France
    AIDS 21:241-3. 2007
    ..The combination of amprenavir, lopinavir and ritonavir (400 mg/day) is durably potent, yielding a sustained virological response (HIV RNA < 50 copies) in 39% of cases...
  29. ncbi request reprint Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir
    Laurence Gerard
    INSERM SC10, Villejuif, France
    Antivir Ther 12:31-9. 2007
    ....
  30. pmc Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients
    Cecile Goujard
    Internal Medicine Department, Bicetre Hospital, Le Kremlin Bicetre, France
    Antimicrob Agents Chemother 47:118-23. 2003
    ..These data support the use of low-dose ritonavir to enhance the level of exposure to amprenavir and increase the efficacy of amprenavir...
  31. ncbi request reprint Interaction between tacrolimus and fumagillin in two kidney transplant recipients
    Nadia Arzouk
    Transplantation 81:136-7. 2006
  32. ncbi request reprint [Antiretroviral agents in HIV-infected patients with cirrhosis]
    Dominique Salmon-Ceron
    Universite Paris V, Faculte Cochin, Service de Maladies Infectieuses, Hospital Cochin, 27 rue du Faubourg Saint Jacques, 75014 Paris
    Presse Med 34:1S45-52. 2005
    ..In any event rigorous monitoring is a must...